ArticleTrials2020

A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.

Joseph C C Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.